[O-29] 一般演題口演セッション29 治療創薬、再生医療2

[O-29-1] Safety and tolerability of conversion to siponimod in MS: interim results of the EXCHANGE study

^○Di Comite Gabriele¹, Bar-or Amit², Weinstock-guttman Bianca³, Mao-draayer Yang⁴, Cox Gina⁵, Cruz Linda-ali⁵, Meng Xiangyi⁵, Su Wendy⁵, Cohan L. Stanley⁶ (1.Novartis Pharma KK, Tokyo, Japan, 2.Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3.Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA, 4.Autoimmunity Center of Excellence, Multiple Sclerosis Center, University of Michigan, Ann Arbor, MI, USA, 5.Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6.Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, USA)